Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt unloaded 4,115 shares of United Therapeutics stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $88.39, for a total value of $363,724.85. Following the completion of the transaction, the chief executive officer now directly owns 140 shares in the company, valued at approximately $12,375. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday, July 31st. Separately, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Finally, analysts at HC Wainwright raised their price target on shares of United Therapeutics from $120.00 to $150.00 in a research note on Wednesday, July 30th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. United Therapeutics has a consensus rating of “Buy” and an average price target of $102.21.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 2.26% on Friday, hitting $91.79. 571,332 shares of the company’s stock traded hands. United Therapeutics has a 52 week low of $70.34 and a 52 week high of $116.65. The stock has a 50-day moving average of $91.0 and a 200-day moving average of $95.89. The company has a market cap of $4.339 billion and a price-to-earnings ratio of 17.34.

United Therapeutics (NASDAQ:UTHR) last released its earnings data on Tuesday, July 29th. The company reported $2.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter last year, the company posted $1.52 earnings per share. United Therapeutics’s revenue was up 15.0% compared to the same quarter last year. Analysts expect that United Therapeutics will post $8.55 EPS for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Receive News & Ratings for United Therapeutics Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co and related companies with Analyst Ratings Network's FREE daily email newsletter.